Global Information
회사소개 | 문의 | 비교리스트

B형 혈우병 : 파이프라인 리뷰

Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 03월 상품 코드 232835
페이지 정보 영문 150 Pages
가격
US $ 2,000 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,781,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,172,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


B형 혈우병 : 파이프라인 리뷰 Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020
발행일 : 2020년 03월 페이지 정보 : 영문 150 Pages

B형 혈우병은 혈액 응고 제IX인자의 부족에 의해 발생하는 유전성 출혈 질환입니다. 충분한 양의 제IX인자가 없으면 혈액을 응고시켜 출혈을 효과적으로 막을 수 없게 됩니다. 주요 증상으로 관절 내부에서의 출혈 및 이에 따른 관절통·종창, 자반, 환상절제에 따른 과잉 출혈, 소화관·요로로부터의 출혈, 코피 등이 있습니다. 주요 치료법으로 결손된 응고인자의 보충 등이 있습니다.

세계의 각국에서의 B형 혈우병(Hemophilia B) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 개요, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

B형 혈우병 개요

치료제 개발

  • B형 혈우병용 파이프라인 제품 : 개요
  • B형 혈우병용 파이프라인 제품 : 기업별
  • B형 혈우병용 파이프라인 제품 : 대학/연구기관별
  • B형 혈우병 치료제 - 개발중인 제품 : 기업별
  • B형 혈우병 치료제 - 연구중인 제품 : 대학/연구기관별

B형 혈우병 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

B형 혈우병 치료제 개발에 참여하고 있는 기업

  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Bayer AG
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • China Biologic Products Inc
  • CSL Ltd
  • Genethon SA
  • Green Cross Corp
  • LFB SA
  • MolMed SpA
  • Novo Nordisk A/S
  • OPKO Biologics Ltd
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • Spark Therapeutics Inc
  • UniQure NV

약제 프로파일

B형 혈우병 치료제 : 개발 휴지 상태의 제품

B형 혈우병 치료제 : 개발이 중지된 제품

B형 혈우병 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

KSM 17.10.31

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Hemophilia B (Factor IX Deficiency), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by ApcinteX Ltd, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by ASC Therapeutics Inc, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Catalyst Biosciences Inc, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by China Biologic Products Holdings Inc, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Expression Therapeutics LLC, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Dormant Projects, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Hemophilia B (Factor IX Deficiency) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Hemophilia B (Factor IX Deficiency), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2020, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 6, 2, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
    • Hemophilia B (Factor IX Deficiency) - Overview
    • Hemophilia B (Factor IX Deficiency) - Therapeutics Development
    • Hemophilia B (Factor IX Deficiency) - Therapeutics Assessment
    • Hemophilia B (Factor IX Deficiency) - Companies Involved in Therapeutics Development
    • Hemophilia B (Factor IX Deficiency) - Drug Profiles
    • Hemophilia B (Factor IX Deficiency) - Dormant Projects
    • Hemophilia B (Factor IX Deficiency) - Discontinued Products
    • Hemophilia B (Factor IX Deficiency) - Product Development Milestones
    • Appendix
Back to Top
전화 문의
F A Q